Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 04 04:00PM ET
2.77
Dollar change
-0.03
Percentage change
-1.07
%
Index- P/E- EPS (ttm)-4.50 Insider Own35.49% Shs Outstand1.09M Perf Week-1.07%
Market Cap3.34M Forward P/E- EPS next Y-5.20 Insider Trans0.00% Shs Float0.78M Perf Month2.02%
Income-4.26M PEG- EPS next Q-2.43 Inst Own0.88% Short Float3.22% Perf Quarter-14.51%
Sales0.48M P/S6.97 EPS this Y-27.44% Inst Trans- Short Ratio0.14 Perf Half Y-46.73%
Book/sh1.34 P/B2.07 EPS next Y33.76% ROA-170.50% Short Interest0.03M Perf Year-67.64%
Cash/sh1.12 P/C2.48 EPS next 5Y- ROE-231.67% 52W Range2.21 - 12.00 Perf YTD-66.05%
Dividend Est.- P/FCF- EPS past 5Y-190.11% ROI-292.24% 52W High-76.92% Beta0.41
Dividend TTM- Quick Ratio2.97 Sales past 5Y20.14% Gross Margin99.40% 52W Low25.34% ATR (14)0.36
Dividend Ex-Date- Current Ratio2.97 EPS Y/Y TTM24.79% Oper. Margin-901.46% RSI (14)47.04 Volatility13.89% 14.38%
Employees7 Debt/Eq0.05 Sales Y/Y TTM0.78% Profit Margin-881.73% Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q29.85% Payout- Rel Volume0.21 Prev Close2.80
Sales Surprise0.00% EPS Surprise0.00% Sales Q/Q-22.75% EarningsNov 27 Avg Volume175.52K Price2.77
SMA201.14% SMA50-11.95% SMA200-39.25% Trades Volume36,338 Change-1.07%
Dec-03-24 08:30AM
Nov-21-24 05:30AM
Nov-12-24 05:30AM
Nov-01-24 04:30PM
Oct-29-24 08:30AM
05:00AM Loading…
Oct-15-24 05:00AM
Oct-09-24 10:47AM
Sep-25-24 08:30AM
Sep-24-24 08:00AM
Aug-27-24 08:00AM
Aug-22-24 05:00AM
Aug-21-24 05:00AM
Aug-12-24 06:52AM
05:00AM
Aug-01-24 04:05PM
08:00AM Loading…
08:00AM
Jul-29-24 05:00AM
May-31-24 08:00AM
May-29-24 12:53PM
08:00AM
May-24-24 01:53PM
May-21-24 08:00AM
Apr-17-24 08:00AM
Apr-05-24 08:00AM
Apr-03-24 08:00AM
Mar-07-24 03:23PM
Mar-05-24 08:00AM
Feb-20-24 08:00AM
Dec-20-23 08:00AM
Nov-12-23 08:20PM
08:00AM Loading…
Nov-10-23 08:00AM
Oct-25-23 04:05PM
Oct-24-23 08:00AM
Oct-23-23 08:45AM
08:30AM
Oct-20-23 08:00AM
Sep-21-23 08:30AM
Jun-13-23 08:30AM
May-15-23 09:15AM
May-14-23 08:12AM
May-01-23 08:30AM
Apr-17-23 08:30AM
Apr-05-23 08:30AM
Mar-31-23 08:00AM
Mar-16-23 08:30AM
Mar-01-23 08:00AM
Jan-11-23 07:30AM
Jan-09-23 08:00AM
Dec-22-22 04:05PM
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaufman Jonathan HSee remarks below.May 14 '24Buy0.7610,0007,590898,849May 15 04:39 PM
Kaufman Jonathan HSee remarks below.Mar 18 '24Buy0.7930,00023,649863,849Mar 19 06:21 PM
Kaufman Jonathan HSee remarks below.Mar 19 '24Buy0.8725,00021,802888,849Mar 19 06:21 PM